➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
AstraZeneca
Dow
McKinsey
McKesson

Last Updated: November 23, 2020

DrugPatentWatch Database Preview

ABBVIE INC Company Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for ABBVIE INC
International Patents:1046
US Patents:54
Tradenames:11
Ingredients:10
NDAs:11
Drug Master File Entries: 15
Patent Litigation for ABBVIE INC: See patent lawsuits for ABBVIE INC

Drugs and US Patents for ABBVIE INC

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie Inc VENCLEXTA venetoclax TABLET;ORAL 208573-001 Apr 11, 2016 RX Yes No 8,722,657   Start Trial Y   Start Trial
Abbvie Inc VENCLEXTA venetoclax TABLET;ORAL 208573-003 Apr 11, 2016 RX Yes Yes   Start Trial   Start Trial
Abbvie Inc VIEKIRA PAK (COPACKAGED) dasabuvir sodium; ombitasvir; paritaprevir; ritonavir TABLET, TABLET;ORAL 206619-001 Dec 19, 2014 RX Yes Yes 8,691,938   Start Trial Y Y   Start Trial
Abbvie Inc VIEKIRA XR dasabuvir sodium; ombitasvir; paritaprevir; ritonavir TABLET, EXTENDED RELEASE;ORAL 208624-001 Jul 22, 2016 DISCN Yes No 8,685,984   Start Trial   Start Trial
Abbvie Inc ORILISSA elagolix sodium TABLET;ORAL 210450-002 Jul 23, 2018 RX Yes Yes 7,419,983   Start Trial Y Y   Start Trial
Abbvie Inc ORILISSA elagolix sodium TABLET;ORAL 210450-001 Jul 23, 2018 RX Yes No 7,056,927   Start Trial Y Y   Start Trial
Abbvie Inc VIEKIRA XR dasabuvir sodium; ombitasvir; paritaprevir; ritonavir TABLET, EXTENDED RELEASE;ORAL 208624-001 Jul 22, 2016 DISCN Yes No 10,105,365   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ABBVIE INC

Paragraph IV (Patent) Challenges for ABBVIE INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Capsules 100 mg ➤ Subscribe 2012-10-31
➤ Subscribe Tablets 145 mg ➤ Subscribe 2007-10-19
➤ Subscribe Tablets 100 mg ➤ Subscribe 2010-12-21
➤ Subscribe Tablets 48 mg ➤ Subscribe 2008-07-01

Supplementary Protection Certificates for ABBVIE INC Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2692346 PA2017033 Lithuania   Start Trial PRODUCT NAME: PIBRENTASVIRAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/17/1213 20170726
2340029 CR 2015 00013 Denmark   Start Trial PRODUCT NAME: PARITAPREVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEROF; REG. NO/DATE: EU/1/14/982 20150119
2203431 575 Finland   Start Trial
2618831 2017/045 Ireland   Start Trial PRODUCT NAME: GLECAPREVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEREOF.; REGISTRATION NO/DATE: EU/1/17/1213 20170726
2203431 300729 Netherlands   Start Trial PRODUCT NAME: DASABUVIR OF ZOUT DAARVAN, WAARONDER DASABUVIR NATRIUMMONOHYDRAAT; REGISTRATION NO/DATE: EU/1/14/983 20150119
2368890 2015/010 Ireland   Start Trial PRODUCT NAME: OMBITASVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/14/982 20150115
2692346 CR 2017 00049 Denmark   Start Trial PRODUCT NAME: PIBRENTASVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/17/1213 20170728
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Moodys
Colorcon
Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.